Teething Tablets, Toothpaste Recalls: Consumer Health Industry News Roundup

Standard Homeopathic recalls Hyland's teething products; ACT enters children's toothpaste market; Sensodyne toothpaste recalled.

FDA's concern about the botanical belladonna on baby teething products prompts Standard Homeopathic Co. to recall all lots of its Hyland’s teething tablets six months after it stopped making the products. In an announcement FDA posted online April 13, the firm said the agency considers belladonna "a serious health hazard to children" and that the substance's effects are unpredictable.

FDA concluded Hyland's Baby and Nighttime Baby Teething Tablets "have been found to contain inconsistent amounts of belladonna alkaloids that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By 

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making the forecasting environment for the pharma industry extremely difficult, the Pink Sheet finds in this infographic analysis.

Manufacturers Can Keep Their Shoes On: FDA PreCheck To Streamline US Facility Applications

 

The program would allow early interactions with FDA staff to speed construction and approval of pharmaceutical manufacturing facilities in the US, but will staff be available?

Titanium Dioxide Stays: EU Decides Not To Pull Plug On Widely Used Excipient

 

While titanium dioxide is banned as a food additive in the EU, the European Medicines Agency has convinced the European Commission to allow its continued use in the many thousands of medicines in which it is currently used.

UK Medicines Shortages Inquiry Eyes Full Reshoring of Drug Manufacturing

 

A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.

More from Compliance